Eunice Wang, MD

Eunice Wang, MD, chief of the leukemia service at the Roswell Park Comprehensive Cancer Center, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia (AML) over the last several years due to the number of new treatment options approved by the FDA.

FDA extended the approval of gemtuzumab ozogamicin (Mylotarg) to include an indication

 for the treatment of newly diagnosed pediatric patients with CD33-positive AML as young as 1 month old. Wang says it is exciting to be involved in the AML therapy field as she believes there are not many other rare cancer types that have seen such an explosion of new agents in the field.

Wang says it is exhilarating to see so many new treatment options for her patients with AML. She has been treating patients for over 15 years, and for 12 years, she primarily gave all patients with AML the same treatment. Because of all the FDA approvals and the development of new agents, she can tailor her treatments specifically to her individual patients to provide them the best outcomes.

At this time, it is important to be aware that AML is made up of many different diseases and subtypes. In order to obtain the best outcome, physicians need to expand their understanding of the disease, the complexity of the disease, and tailor their treatments in a precision medicine-based way for individual patients with AML.

<<View more resources and information regarding AML

Videos

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

Eunice Wang, MD, chief of the leukemia service at the Roswell Park Comprehensive Cancer Center, discusses the new era of treatment for patients with acute myeloid leukemia (AML) after

With these approvals, physicians are questioning how necessary the standard backbone chemotherapy low-dose cytarabine and anthracycline-based treatments are; these agents have been the standard since the 1970s for younger and fitter patients.

For the last few years, physicians have been using low-dose hypomethylating agents for older patients. In the last year, there has been a breakthrough in terms of combination therapy with low-dose chemotherapy and oral agents.

Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.

Updates in the Treatment Landscape of AML

Eunice Wang, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients &ge; 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

ALL is highly curable in pediatric patients, though the cure rate in adults is only 40-50%

Patients in this trial are randomized to receive either standard chemotherapy or standard chemotherapy in addition to Marqibo

Marqibo is currently approved in the relapsed/refractory setting but has not been tested in older adults

Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients â‰¥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

Author | Eunice Wang, MD

Articles

Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

Updates in the Treatment Landscape of AML

Marqibo for the Treatment of Older Patients With ALL